Navigation Links
Poniard Pharmaceuticals Announces $6.3 Million Financing
Date:3/15/2010

h the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOURCE Poniard Pharmaceuticals, Inc.

Back to top

RELATED LINKS
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
2. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
3. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
6. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
9. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
(Date:8/29/2014)... 29, 2014 Does your doctor know what you,re ... have recommended marijuana to the over 112,000 currently registered patients ... majority of the other roughly 20,300+ active physicians listed with ... about it – even though a poll in February 2014 ... they have tried it. "With marijuana legalization ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Chimerix, Inc., a biotechnology company developing orally-available antiviral ... data for CMX001 in a late-breaker presentation at ... and Chemotherapy (ICAAC, Chicago – September 17-20).   ... Infectious Diseases Service at Memorial Sloan-Kettering Cancer Center ...
... YORK, Sept. 16, 2011 MDC Partners ( ... a majority stake in leading healthcare and pharma ... ( www.concentricpharma.com ).  The partnership with Concentric marks ... growing healthcare marketing sector and positions MDC to ...
Cached Medicine Technology:Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 2Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 3MDC Partners Launches Integrated Healthcare Marketing Platform With Acquisition of Majority Stake in Concentric Pharma Advertising 2
(Date:8/29/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Glass ... The report then explores global and China’s top ... capacity, Production value, and market share etc. , ...
(Date:8/29/2014)... Healthpointe is proud to welcome to its ... be practicing out of Healthpointe’s newest office directly adjacent ... orthopedic team, Dr. Rodas is board-certified in ... occupational medicine. , Among Dr. Rodas’ many impressive ... Raytheon, the world-class defense and aerospace company. Additionally, Dr. ...
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new ... achieve great results in hair transplantation. One of these ... an FUE method that harvests facial hair for transplanting to ... patients whose hair loss classification is 5 and above achieve ... great alternative for those advanced hair loss patients who may ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... to Chapman University Physical Therapy students via Clinical ... Chapman University will be shadowing Healthpointe providers and ... allow them to develop clinical experience and learn ... Therapy students will gain insight into several patient ...
(Date:8/29/2014)... (HealthDay News) -- Astronauts may be at heightened ... human immune systems, a new study suggests. That ... to asteroids, the moon and Mars undertaken in the ... space can be dangerous, NASA researchers say. They ... blood of International Space Station crew members remains relatively ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2
... As part of its ongoing commitment to keeping ... recognized leader in innovative healthcare administration for over 20 ... new full-service pharmacy benefit management (PBM) program, MagnaCareRx. ... pharmacy benefit management. With costs rising, plan sponsors can,t ...
... findings , TUESDAY, July 7 (HealthDay News) -- Parents ... that show a reduced-dose schedule for the pneumococcal vaccine ... The current recommended dose schedule for 7-valent pneumococcal conjugate ... age of 6 months, followed by a booster vaccination ...
... linked in studies to lower incidence of type 2 diabetes ... of a protein created by fat cells are associated with ... protein, adiponectin, appears to have anti-inflammatory and insulin-sensitizing capabilities, according ... the Journal of the American Medical Association . , ...
... Ulrich Stroeher, Chairman of the Advisory,Board of Berlin Heart, today ... the company on 30 September 2009. , ... one of the,intellectual fathers of the successful ventricular assist device ... this area as,coordinator for projects with external cooperation partners. He ...
... , ATLANTA, July 7 Crawford Canada,s Bill Johnstone ... Company,s (NYSE: CRDA ; CRDB) Global Technical ... designed to more effectively coordinate and grow this market-leading ... is a major differentiator for Crawford worldwide in the ...
... ... ... roving weather star, Al Roker, has packed up his Penske truck once again to hit ... consecutive year, "Lend a Hand" continues its mission to help small charities across the country ...
Cached Medicine News:Health News:MagnaCare Answers Need for New Prescription Drug Program 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 3Health News:Berlin Heart Announces Restructuring of Management 2Health News:Bill Johnstone Named Senior Vice President of Crawford's Global Technical Services for the Americas 2Health News:Supergoop! Award-Winning SPF 30 Sunscreen & Skin Protection Lotion Featured On The Today Show 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: